Results 21 to 30 of about 56,610 (260)
Frontiers in Immunology, 2019 The successful generation of T cell-mediated immunity for the treatment of cancer has been a major focal point of research. One of the critical strategies of cancer immunotherapy is to efficiently activate antigen-specific CD8 T cells in the ...
Jin-Zhi Lai +5 more
doaj +1 more source
Adoptive B cell therapy for chronic viral infection
Frontiers in Immunology, 2022 T cell-based therapies have been widely explored for the treatment of cancer and chronic infection, but B cell-based therapies have remained largely unexplored.
Young Rock Chung +4 more
doaj +1 more source
Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
Frontiers in Veterinary Science, 2021 Osteosarcoma is the most common primary bone tumor in both humans and dogs. It is a highly metastatic cancer and therapy has not improved significantly since the inclusion of adjuvant chemotherapy into disease treatment strategies.
William C. Kisseberth, Dean A. Lee
doaj +1 more source
Frontiers in Oncology, 2022 Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies.
Yuan Chen +6 more
doaj +1 more source
Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors
Frontiers in Immunology, 2021 Adoptive T cell therapy has emerged as a revolutionary immunotherapy for treating cancer. Despite immense promise and clinical success in some hematologic malignancies, limitations remain that thwart its efficacy in solid tumors.
Preethi Bala Balakrishnan +1 more
doaj +1 more source
Frontiers in Immunology, 2023 Recurrent neoepitopes are cancer-specific antigens common among groups of patients and therefore ideal targets for adoptive T cell therapy. The neoepitope FSGEYIPTV carries the Rac1P29S amino acid change caused by a c.85C>T missense mutation, which is
Lena Immisch +15 more
doaj +1 more source
Adoptive T-cell therapy for Hodgkin lymphoma [PDF]
Blood Advances, 2021 AbstractAlthough CAR T-cell therapy is US Food and Drug Administration–approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus–specific cytotoxic T lymphocytes and CD30 CAR T cells have ...
Carrie Ho +3 more
openaire +2 more sources
European Journal of Case Reports in Internal MedicineIntroduction: Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths; non-small cell lung cancer (NSCLC) constitutes about 85% of lung cancer cases, with ALK fusions representing 3–6% of them.
Brenda Paola Rodriguez Arroyo +5 more
doaj +1 more source
Adoptive T-Cell Therapy for Cancer [PDF]
, 2016 Recent developments have demonstrated that immunotherapies are capable of achieving durable antitumor responses in patients with metastatic cancer. One modality that has been able to induce durable complete regressions in patients with melanoma has been adoptive cell therapy (ACT).
James C, Yang, Steven A, Rosenberg
openaire +2 more sources
The Cancer Journal, 2010 Building on the principals that the adoptive transfer of T cells can lead to the regression of established tumors in humans, investigators are now further manipulating these cells using genetic engineering. Two decades of human gene transfer experiments have resulted in the translation of laboratory technology into robust clinical applications.
Richard A, Morgan +2 more
openaire +2 more sources